Subsequent therapy
| . | All patients receiving subsequent treatment (n = 38) . |
|---|---|
| IMiD-based regimen, n (%) | |
| Pomalidomide-dexamethasone | 15 (39) |
| Pomalidomide-cyclophosphamide-dexamethasone | 6 (16) |
| Pomalidomide-prednisone | 2 (5) |
| Lenalidomide-cyclophosphamide-prednisone | 2 (5) |
| CELMoD-based regimen, n (%) | |
| Iberdomide ± dexamethasone | 10 (26) |
| PI-based regimen, n (%) | |
| Bortezomib-cyclophosphamide-dexamethasone | 1 (3) |
| Carfilzomib-dexamethasone | 1 (3) |
| IMiD + monoclonal antibody, n (%) | |
| Elotuzumab-pomalidomide-dexamethasone | 1 (3) |
| . | All patients receiving subsequent treatment (n = 38) . |
|---|---|
| IMiD-based regimen, n (%) | |
| Pomalidomide-dexamethasone | 15 (39) |
| Pomalidomide-cyclophosphamide-dexamethasone | 6 (16) |
| Pomalidomide-prednisone | 2 (5) |
| Lenalidomide-cyclophosphamide-prednisone | 2 (5) |
| CELMoD-based regimen, n (%) | |
| Iberdomide ± dexamethasone | 10 (26) |
| PI-based regimen, n (%) | |
| Bortezomib-cyclophosphamide-dexamethasone | 1 (3) |
| Carfilzomib-dexamethasone | 1 (3) |
| IMiD + monoclonal antibody, n (%) | |
| Elotuzumab-pomalidomide-dexamethasone | 1 (3) |